A cancer patient paying Rs 26,072 for a single injection of Fulvestrant will, from 9 November 2026, pay just Rs 5,491 — a cut of nearly 79 percent. Union Coal and Mines Minister and BJP Telangana president G. Kishan Reddy announced on 2 November 2026 that the central government has sharply reduced prices across 543 brands of cancer medicines, delivering what he described as major relief to poor and middle-class patients.

What changes on 9 November — and for whom

The notification covers 137 non-scheduled cancer drugs, targeting trade margins rather than just manufacturer prices. Rationalising trade margins — the markups added by stockists and retailers between factory gate and patient — is a precise tool: it leaves manufacturing economics largely untouched while directly cutting what a patient pays at the counter.

Fulvestrant, an injectable hormone-therapy drug used primarily in advanced breast cancer, is the headline example: its price crashes from Rs 26,072 to Rs 5,491. For families already stretched by long oncology treatment courses, that single line item can mean the difference between continuing and abandoning therapy.

The NPPA's long campaign on oncology pricing

The National Pharmaceutical Pricing Authority (NPPA), the statutory body empowered under the Drugs (Prices Control) Order, 2013, has been the engine behind repeated rounds of cancer-drug price intervention. Earlier notifications in 2018 and 2019 had already placed ceiling prices and margin caps on dozens of anti-cancer medicines — this latest round extends that arc to a significantly larger basket of 543 brands.

Non-scheduled drugs sit outside the NPPA's direct price-ceiling powers, but the DPCO framework allows margin rationalisation as a parallel lever. It is a mechanism successive governments have deployed precisely because oncology drugs — often patented, often imported — resist blunt price caps without disrupting supply.

Why out-of-pocket costs define India's cancer burden

India's cancer burden is enormous and growing. Out-of-pocket expenditure on medicines remains the single largest driver of catastrophic health spending for Indian households, and oncology drugs — expensive, recurring, rarely substitutable — sit at the worst end of that problem. By targeting 137 non-scheduled brands where trade margins had remained unregulated, the government is addressing a gap that ceiling prices alone could not close.

Compliance monitoring by the NPPA once the 9 November effective date passes will be the real test — whether revised maximum retail prices actually reach chemist counters and hospital pharmacies across every state.

For millions of families counting every rupee through a treatment cycle, the numbers land on 9 November. Watch whether they hold.